Advanced Enzyme Technologies Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Advanced Enzyme Technologies wird ein Gewinn- und Umsatzwachstum von 26.7% bzw. 15.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 26.8% pro Jahr wachsen soll.
Wichtige Informationen
26.7%
Wachstumsrate der Gewinne
26.8%
EPS-Wachstumsrate
Chemicals Gewinnwachstum | 22.8% |
Wachstumsrate der Einnahmen | 15.6% |
Zukünftige Eigenkapitalrendite | n/a |
Analystenabdeckung | Low |
Zuletzt aktualisiert | 17 May 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar
Aug 20We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now
Jul 19Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
Jul 13Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
Apr 08Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Sep 23Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital
Feb 03Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Aug 11With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting
May 13Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture
Mar 28The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?
Mar 13Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)
Feb 21Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 18I Built A List Of Growing Companies And Advanced Enzyme Technologies (NSE:ADVENZYMES) Made The Cut
Feb 03What Kind Of Investors Own Most Of Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)?
Jan 19What Do The Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Tell Us?
Dec 28The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 114%, So Why Not Pay It Some Attention?
Dec 13Have Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Insiders Been Selling Their Stock?
Nov 28Are Strong Financial Prospects The Force That Is Driving The Momentum In Advanced Enzyme Technologies Limited's NSE:ADVENZYMES) Stock?
Nov 20Here's Why I Think Advanced Enzyme Technologies (NSE:ADVENZYMES) Might Deserve Your Attention Today
Nov 05What You Need To Know About Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Investor Composition
Oct 21Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
3/31/2026 | 7,888 | 2,114 | 2,105 | 2,405 | 1 |
3/31/2025 | 7,014 | 1,797 | 2,892 | 3,192 | 1 |
9/30/2024 | 6,194 | 1,371 | 904 | 1,422 | N/A |
6/30/2024 | 6,311 | 1,386 | N/A | N/A | N/A |
3/31/2024 | 6,239 | 1,333 | 941 | 1,414 | N/A |
12/31/2023 | 6,048 | 1,371 | N/A | N/A | N/A |
9/30/2023 | 5,859 | 1,248 | 965 | 1,327 | N/A |
6/30/2023 | 5,668 | 1,166 | N/A | N/A | N/A |
3/31/2023 | 5,406 | 1,056 | 1,022 | 1,404 | N/A |
12/31/2022 | 5,337 | 979 | N/A | N/A | N/A |
9/30/2022 | 5,251 | 960 | 806 | 1,164 | N/A |
6/30/2022 | 5,135 | 995 | N/A | N/A | N/A |
3/31/2022 | 5,294 | 1,196 | 941 | 1,223 | N/A |
12/31/2021 | 5,309 | 1,268 | N/A | N/A | N/A |
9/30/2021 | 5,350 | 1,424 | 1,127 | 1,374 | N/A |
6/30/2021 | 5,325 | 1,500 | N/A | N/A | N/A |
3/31/2021 | 5,018 | 1,459 | 1,434 | 1,630 | N/A |
12/31/2020 | 4,820 | 1,459 | N/A | N/A | N/A |
9/30/2020 | 4,569 | 1,364 | 978 | 1,472 | N/A |
6/30/2020 | 4,481 | 1,301 | N/A | N/A | N/A |
3/31/2020 | 4,440 | 1,293 | 904 | 1,409 | N/A |
12/31/2019 | 4,480 | 1,302 | N/A | N/A | N/A |
9/30/2019 | 4,366 | 1,210 | 1,147 | 1,276 | N/A |
6/30/2019 | 4,288 | 1,148 | N/A | N/A | N/A |
3/31/2019 | 4,220 | 1,111 | 1,162 | 1,286 | N/A |
12/31/2018 | 4,194 | 1,061 | N/A | N/A | N/A |
9/30/2018 | 4,261 | 1,068 | N/A | N/A | N/A |
6/30/2018 | 4,199 | 1,039 | N/A | N/A | N/A |
3/31/2018 | 3,918 | 901 | N/A | 1,160 | N/A |
12/31/2017 | 3,660 | 837 | N/A | N/A | N/A |
9/30/2017 | 3,213 | 725 | N/A | N/A | N/A |
6/30/2017 | 3,127 | 793 | N/A | N/A | N/A |
3/31/2017 | 3,290 | 915 | N/A | 1,074 | N/A |
12/31/2016 | 3,260 | 942 | N/A | N/A | N/A |
9/30/2016 | 3,404 | 998 | N/A | N/A | N/A |
6/30/2016 | 3,184 | 854 | N/A | N/A | N/A |
3/31/2016 | 2,938 | 759 | N/A | 934 | N/A |
3/31/2015 | 2,233 | 510 | N/A | 537 | N/A |
3/31/2014 | 2,397 | 201 | N/A | 433 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ADVENZYMESDas prognostizierte Gewinnwachstum (26.7% pro Jahr) liegt über der Sparquote (6.7%).
Ertrag vs. Markt: ADVENZYMESDie Erträge des Unternehmens (26.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (18% pro Jahr).
Hohe Wachstumserträge: ADVENZYMESEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: ADVENZYMESDie Einnahmen des Unternehmens (15.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (10.4% pro Jahr).
Hohe Wachstumseinnahmen: ADVENZYMESDie Einnahmen des Unternehmens (15.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ADVENZYMES in 3 Jahren voraussichtlich hoch sein wird